Pharmafile Logo
Pharmafocus logo
Advanced Search

GW Pharma

Showing 3 posts of 18 posts found.

gwpharma

Cannabis-based treatment scores Phase 3 successes for GW Pharma

December 6, 2016
Manufacturing and Production, Research and Development GW Pharma, cannabidiol

UK-based GW Pharmaceuticals, a biopharmaceutical firm focused on the development of novel cannabinoid therapies, has unveiled new efficacy data for …

News
gwpharma

GW Pharma’s cannabis-based epilepsy drug granted orphan designation by FDA

April 21, 2016
Research and Development, Sales and Marketing GW Pharma, cannabis, cannabis-based, epilepsy

GW Pharmaceuticals (NASDAQ: GWPH) has announced that the US Food and Drug Administration has granted its cannabis-based epilepsy drug, Epidiolex …

News
gwpharma

GW Pharma shares more than double after positive Phase III trials for epilepsy drug

March 15, 2016
Manufacturing and Production, Research and Development Epidiolex, GW Pharma, US FDA, epilepsy in children, phase III

Shares in UK-based GW Pharmaceuticals (Nasdaq: GWPH) more than doubled on the Nasdaq Monday after the company announced positive results …

News
The Gateway to Local Adoption Series

Latest content

Siemens Healthineers opens 10m euro R&D centre for laboratory equipment in Ireland

February 19, 2026

Everdrone announces new board of directors to drive expansion

February 19, 2026

Regeneron announces presentations of new data on Eylea HD for retinal disease

February 18, 2026

Indegene completes acquisition of Cake Health

February 18, 2026

Gedeon Richter UK acquires rights to schizophrenia treatment Reagila from Recordati Pharmaceuticals

February 17, 2026